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Background: Therapeutic modalities effective in patients with progressive forms of multiple sclerosis (MS) are
limited. In a murine model of progressive MS, the sustained disability during the chronic phase of experimental
autoimmune encephalomyelitis (EAE) correlated with elevated expression of interleukin (IL)-6, a cytokine with
pleiotropic functions and therapeutic target for non-central nervous system (CNS) autoimmune disease. Sustained
IL-6 expression in astrocytes restricted to areas of demyelination suggested that IL-6 plays a major role in disease
progression during chronic EAE.
Methods: A progressive form of EAE was induced using transgenic mice expressing a dominant negative interferon-γ
(IFN-γ) receptor alpha chain under control of human glial fibrillary acidic protein (GFAP) promoter (GFAPγR1Δ mice).
The role of IL-6 in regulating progressive CNS autoimmunity was assessed by treating GFAPγR1Δ mice with anti-IL-6
neutralizing antibody during chronic EAE.
Results: IL-6 neutralization restricted disease progression and decreased disability, myelin loss, and axonal damage
without affecting astrogliosis. IL-6 blockade reduced CNS inflammation by limiting inflammatory cell proliferation;
however, the relative frequencies of CNS leukocyte infiltrates, including the Th1, Th17, and Treg CD4 T cell subsets,
were not altered. IL-6 blockade rather limited the activation and proliferation of microglia, which correlated with
higher expression of Galectin-1, a regulator of microglia activation expressed by astrocytes.
Conclusions: These data demonstrate that astrocyte-derived IL-6 is a key mediator of progressive disease and
support IL-6 blockade as a viable intervention strategy to combat progressive MS.
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Multiple sclerosis (MS) is characterized by focal inflamma-
tion within the central nervous system (CNS), demyelin-
ation, axonal damage, and neurological disability [1]. The
precise basis for tissue damage associated with MS is un-
clear. However, experimental autoimmune encephalomy-
elitis (EAE), a rodent model with numerous characteristics
in common with MS, has been essential in understanding
the mechanisms underlying MS pathogenesis and has* Correspondence: stohlms2@ccf.org
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[2,3]. EAE is mediated by self-reactive T cells directed
toward components of myelin [4] secreting interleukin
(IL)-17, interferon-γ (IFN-γ), and granulocyte-macrophage
colony-stimulating factor [5,6]. Effective therapeutic mo-
dalities are currently available for the prevalent relapsing
and remitting form of MS. By contrast, no effective therap-
ies have been identified for the treatment of the chronic
progressive forms of MS [7]. Indeed, most of the current
EAE models provide insight into the acute onset and the
relapsing remitting disease course, without the ability to
mimic the irreversible progressive disability observed in
progressive MS [3,8]. We recently developed a murine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in which astrocytes are deficient in IFN-γ signaling charac-
terized by prolonged disability and increased mortality [9].
Several pathological features of progressive MS, including
increased demyelination, axonal loss, and astrogliosis, were
observed in GFAPγR1Δ mice with chronic EAE [9]. More-
over, the progressive disability and sustained demyelination
correlated with elevated expression of IL-6, a cytokine with
pleiotropic functions and a therapeutic target for non-CNS
autoimmune diseases, such as rheumatoid arthritis [10].
Inhibition of IL-6 signaling is also effective in several mur-
ine models of inflammatory diseases, including colitis,
asthma, and cancer [11-13].
IL-6, an activator of acute phase responses, is expressed
during all forms of inflammation [14], including within
the CNS of MS patients [15] and animals with acute EAE
[16]. IL-6 is crucial in the induction of CNS autoimmune
attack by promoting peripheral induction of self-reactive
T cells, facilitating their recruitment into the CNS and
limiting the regulatory T cell (Treg) response. Mice lack-
ing IL-6 are resistant to EAE [17-19], consistent with the
absence of inflammatory cells within the CNS paren-
chyma [18,19] and its essential role in T cell activation
[20]. IL-6 also interacts with CNS endothelial cells result-
ing in increased vascular cell adhesion molecule-1
(VCAM-1) expression, a prerequisite for CNS entry of
integrin α4β1+ effector T cells [21]. In addition to facili-
tating CNS entry of autoimmune T cells, IL-6 is required
for activation of encephalitogenic Th17 cells [22] and
enhances acute inflammation by suppressing expression
of the Foxp3 transcription factor [23], thereby limiting
the suppressive activity of Treg. In addition to a pro-
inflammatory role in the context of acute inflammation,
IL-6 also exhibits a variety of functions within the CNS
either totally or partially independent of its role in in-
flammation. For example, it is associated with protective
CNS functions by promoting neuronal survival and re-
generation [24,25], as well as inducing oligodendrocyte
differentiation, thereby facilitating myelin repair [26].
Astrocytes are the primary cells secreting IL-6 in the
CNS of both patients with MS and in rodents with acute
EAE [27,28]. Targeted inhibition of NF-κB in astrocytes
is associated with EAE recovery by reducing inflamma-
tion and increasing both IL-6 expression [29] and
remyelination [30]. These data suggest a protective role
for IL-6 during CNS autoimmunity. Nevertheless, con-
stitutive IL-6 expression by astrocytes results in neur-
onal damage and astrogliosis [31]. Similarly, inhibition
of IFN-γ signaling to astrocytes results in a progressive
form of EAE and increased IL-6 [9], supporting a dele-
terious function of IL-6 during progressive disease.
Therefore, the role of IL-6 during the remission stages
of CNS autoimmunity or during progressive disease re-
mains unclear.Astrocytes, in addition to secreting IL-6 during both
MS and acute EAE, also actively regulate microglia at
multiple levels during both pro-inflammatory injury and
repair. Astrocytes attenuate microglial activation, reduce
microglial secretion of both pro- and anti-inflammatory
cytokines, as well as limit microglial-supported T cell
proliferation in vitro [32]. Specific gene deletions in
astrocytes confirm they both attenuate and activate
microglia in vivo during EAE. For example, Galectin-1
secretion by astrocytes limits microglial activation and
clinical symptoms [33]. Similarly, expression of a domin-
ant negative NF-κB repressor in astrocytes diminishes
clinical EAE associated with attenuated tumor necrosis
factor (TNF) secretion by microglia [29]. By contrast,
inhibiting astrocyte IFN-γ signaling sustains disability
and correlates with increased TNF and IL-6 [9]. Thus,
astrocytes, which play critical roles in both acute and
chronic CNS injury, respond to changes by actively shaping
the environment and influence repair by altering the de-
structive or protective state of microglia.
The role of IL-6 in regulating progressive CNS auto-
immunity was examined in the transgenic GFAPγR1Δ
mouse model of progressive EAE [34]. Similar to acute
EAE, neither the inability of the astrocytes to respond to
IFN-γ nor the progressive clinical phenotype altered the
predominant expression of IL-6 by astrocytes. Blocking
IL-6 activity limited progression of clinical symptoms,
promoted clinical recovery, and restrained the extent of
demyelination and axonal damage. However, neither the
composition of leukocyte population nor their predom-
inant cytokine secretion patterns were altered. IL-6
neutralization reduced the frequency of both activated
macrophages and microglia, but selectively decreased
the sustained proliferation of microglia associated with
progressive disease, suggesting a differential effect on
microglia versus macrophages. These data indicate that
sustained IL-6 secretion by astrocytes during progressive
disease is deleterious to both clinical disability and tissue
damage and that these affects may be mediated indirectly
via microglia. IL-6 blockade may thus provide a viable
intervention approach in secondary progressive or pri-
mary progressive MS, for which few therapeutic modal-
ities are currently available.Materials and methods
Mice
Homozygous H-2b GFAP/IFN-γR1ΔIC (GFAPγR1Δ) trans-
genic mice [34], expressing a dominant negative IFN-γ re-
ceptor alpha chain under control of human glial fibrillary
acidic protein (GFAP) promoter, were bred locally. C57BL/6
(H-2b) wild-type (WT) mice were purchased from the
National Cancer Institute (Frederick, MD, USA). All proce-
dures were performed in compliance with protocol number
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Experimental autoimmune encephalomyelitis
EAE was induced by subcutaneous injection of 300 μg
myelin oligodendrocyte glycoprotein (MOG)35–55 peptide
emulsified in phosphate-buffered saline (PBS) and incom-
plete Freund’s adjuvant (IFA; Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 5 mg/ml Mycobacterium
tuberculosis, strain H37Ra (Difco, Detroit, MI, USA), as
previously described [9]. Mice were immunized with
200 μl emulsion distributed subcutaneously over two flank
sites. One hundred nanograms of pertussis toxin (Sigma-
Aldrich) was injected intraperitoneally (i.p.) on the day of
initial immunization and 48 h later. Animals were scored
daily in a blinded fashion for clinical symptoms as follows:
0 = no signs of disease; 1 = flaccid tail or hind limb weak-
ness; 2 = flaccid tail and hind limb weakness, loss of right-
ing reflex; 3 = partial hind limb paralysis; 4 = complete
hind limb paralysis; 5 =moribund or dead.
Anti-IL-6 treatment
The MP5-20 F3 hybridoma secreting a rat IgG2a IL-6
neutralizing monoclonal antibody (mAb) and the con-
trol GL-113 hybridoma secreting a rat IgG1 mAb spe-
cific for β-galactosidase (β-gal) were originally obtained
from Dr. Robert Coffman (DNAX Corp, Palo Alto, CA,
USA). Hybridomas were adapted to BD Cell Serum-
Free Medium (BD, Bedford MA, USA) and the serum-
free mAb collected after propagation of the hybridoma
in a BD CELLine device. Ig concentrations were deter-
mined by optical density at 480 nM, diluted to 1 mg/ml
in endotoxin-free PBS, and stored at −20°C until use.
Mice were divided into two groups of equivalent average
clinical scores and injected i.p. with 500 μg mAb on the
specified days post MOG35–55 peptide immunization.
Isolation of CNS-derived cells and flow cytometry
Mice were perfused with ice-cold PBS before the brain
and spinal cord were harvested and homogenized in
Dulbecco’s PBS using Tenbroeck tissue grinders (Kimble
Chase, Vineland, NJ, USA). Mononuclear cells were con-
centrated from the homogenates by centrifugation at
450 × g for 7 min at 4°C. Cell pellets were resuspended in
RPMI 1640 medium supplemented with 25 mM HEPES
(pH 7.2) and adjusted to 30% Percoll (Pharmacia, Uppsala,
Sweden). A 70% Percoll underlay was added prior to
centrifugation at 800 × g for 30 min at 4°C. Cells were re-
covered from the 30%/70% interface, washed with RPMI,
and then incubated for 10 min on ice in fluorescence acti-
vated cell sorting (FACS) buffer with mouse serum and
anti-CD16/CD32 mAb (clone 2.4G2, BD Biosciences, San
Diego, CA, USA) to limit unspecific binding. FITC-, PE-,
PerCP-, and APC-conjugated surface markers (all fromBD Biosciences unless specified), including CD45 (30-
F11), CD4 (GK1.5), CD11b (clone m1/70), I-A/I-E (clone
2G9), and F4/80 (Serotec, Raleigh, NC, USA), were then
added and cells incubated for 30 min on ice. Cells were
washed with FACS buffer prior to analysis. For intracellu-
lar staining, CNS-derived cells were stimulated for 6 h
with phorbol 12-myristate 13-acetate (PMA) (10 ng/ml)
(Acros Organics, Geel, Belgium) and ionomycin (1 μM)
(Calbiochem, Spring Valley, CA, USA), with Monensin
(2 μM) (Calbiochem) added for the last 2 h. Following
stimulation, surface molecules were detected as described
above. Cells were permeabilized using Cytofix/Cytoperm
solution (BD Biosciences) and incubated for 30 min on ice
with fluorescent mAb specific for IFN-γ (XMG1.2; BD
Biosciences), IL-17 (TC11-18H10; BD Biosciences), or
Foxp3 (FJK-16 s; eBiosciences). Cells were then washed
using Perm/Wash buffer according to the manufacturer’s
instructions. For proliferation, 1 mg of bromodeoxyuridine
(BrdU) (BD Biosciences) in PBS was administrated i.p.
24 h prior to sacrifice. Mononuclear cells were prepared
from the CNS as described above, stained for surface mol-
ecules, and subsequently stained for intranuclear BrdU ac-
cording to the manufacturer’s instructions using the FITC
BrdU flow kit (BD Biosciences). Data were acquired on a
FACSCalibur flow cytometer (BD Biosciences) and ana-
lyzed using FlowJo software (TreeStar Inc., Ashland, OR,
USA).Real-time PCR
Following PBS perfusion, snap-frozen brains were placed
into TRIzol (Invitrogen, Grand Island, NY, USA) and
homogenized using a TissueLyser with stainless beads
(Qiagen, Valencia, CA, USA). RNA extraction was per-
formed according to the manufacturer’s instructions
followed by DNase I (Ambion, Austin, TX, USA) treat-
ment for 30 min at 37°C. cDNA was then synthetized
using M-MLV Reverse Transcriptase (Invitrogen), oligo-
dT primers (20 μM) (Promega, Madison, WI, USA), and
random primers (20 μM) (Promega). Gene expression
analysis was performed by quantitative real-time PCR using
a 7500 Fast real-time PCR system (Applied Biosystems,
Foster City, CA, USA), SYBR Green Master Mix (Applied
Biosystems), and the following primers: GAPDH: F: 5′-T
GCACCACCAACTGCTTAG-3′, R: 5′-GGATGCAGGG
ATGATGTTC-3′; GFAP: F: 5′- CAGTGTGTCAGCCC
CACTGA-3′, R: 5′- CAGTGTGTCAGCCCCACTGA-3′.
Galectin-1 and heme oxygenase-1 mRNA levels were ana-
lyzed using TaqMan primers and 2X Universal TaqMan
Fast Master Mix (Applied Biosystems). Transcript levels
were normalized to the housekeeping gene GAPDH and
converted to a linearized value using the following formula:
2 CT
GAPDH− CTGeneð Þ  1; 000, where CT represents the thresh-
old cycle value.
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Mice were perfused with ice-cold PBS and spinal cords
fixed in Zn Formalin. Spinal cords were separated into
six sections, two of each corresponding to the cervical,
thoracic, and lumbar regions and embedded in paraffin.
Cross sections (6 μm) were stained with hematoxylin
and eosin (H&E) or luxol fast blue (LFB). For identifi-
cation of activated astrocytes and axonal damage, sec-
tions were incubated with mouse anti-GFAP (AbCam,
Cambridge, MA, USA), SMI-31/SMI-32 (Stenberger
Monoclonals Inc., Lutherville, MD, USA), or anti-amyloid
precursor protein (APP) mAb (Millipore, Billerica, MA,
USA) overnight at 4°C. Biotinylated goat anti-mouse Ab
was added for 1 h at room temperature (RT). Sections
were then incubated with Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) and 3,3′-diamino-
benzidine (Sigma-Aldrich). For IL-6 detection, heat-
mediated antigen retrieval was performed in 0.1 M
citrate buffer, pH 6.0. Sections were then incubated in
0.3% H2O2 for 20 min followed by rabbit anti-IL-6 Ab
(AbCam) overnight at RT. Biotinylated anti-rabbit Ab
was added for 30 min at RT. Staining was revealed with
Vectastain ABC kit and 3,3′-diaminobenzidine. Stained
tissue sections of all six levels on individual glass slides
were scanned with an Aperio ScanScope (Aperio, Vista,
CA, USA) at 40× and digitally imaged at high resolution.
Aperio software was used to quantify areas of demyelin-
ation. Axonal damage was quantitated by counting the
number of APP+ axons in lesions at all six levels and nor-
malized to 100 μm2 of demyelinated lesion area.
Confocal microscopy
Mice were anesthetized and perfused with 4% parafor-
maldehyde (PFA) in PBS. Spinal cords were removed,
separated into portions as described above, and post-
fixed in 4% PFA for additional 24 h. Tissues were cryo-
protected in 20% glycerol for 24 h before 30-μm free-
floating sections were prepared with a sliding microtome
(Leica Microsystems, Wetzlar, Germany). Double immu-
nolabeling was performed as previously described [35].
Briefly, sections were microwaved in 0.01 M citrate
buffer (pH 6.0) followed by pretreatment with 1% Triton
X in PBS. Sections were blocked with PBS containing
3% normal goat serum and 0.01% Triton X for 30 min
and incubated with primary Ab diluted in blocking reagent
overnight at 4°C (rabbit anti-GFAP, Dako, Carpenteria, CA,
USA, 1:1,000; mouse anti-Iba-1, CCF Hybridoma Core,
Cleveland, OH, USA, 1:250; goat anti-IL-6, R&D Systems,
Minneapolis, MN, USA, 1:20). To confirm specificity, pri-
mary Abs were omitted on adjacent sections. The sections
were washed and incubated with species-specific secondary
Abs conjugated to FITC or Cy5 (Jackson ImmunoResearch,
West Grove, PA, USA) for 2 h at RT. Sections were rinsed,
mounted with VECTASHIELD (Vector Labs, Burlingame,CA, USA) and examined on a Leica TCS confocal micro-
scope (Leica Microsystems). Images were analyzed off-
line with Volocity software version 6.1.2 (PerkinElmer,
Waltham, MA, USA).
Statistical analysis
Data represent the mean ± SEM and significance was de-
termined by two-tailed Student’s t test or ANOVA with
Bonferroni post-test. A value of P < 0.05 was considered
statistically significant. Graphs were plotted using Graph-
Pad Prism 4.0c software.
Results
Astrocytes secrete IL-6 during progressive EAE
Astrocytes are the predominant source of IL-6 in the
CNS of patients with MS and mice with acute EAE [27],
and during acute EAE, its expression is independent of
the ability of astrocytes to respond to IFN-γ [9]. By con-
trast, progressive EAE in GFAPγR1Δ mice, in which the
astrocytes are unable to respond to IFN-γ, correlated
with sustained IL-6 mRNA expression [9]. Its adverse
role within the CNS [36] suggested that IL-6 may con-
tribute to progressive disease. As numerous cell types in-
cluding myeloid cells and microglia can secrete IL-6, we
determined if the inability of astrocytes to respond to
IFN-γ signaling altered the cellular source or distribu-
tion of IL-6 during acute and chronic/progressive dis-
ease. The majority of cells secreting IL-6 during acute
EAE in both WT and GFAPγR1Δ mice co-express GFAP,
confirming their identity as astrocytes (Figure 1A). By
contrast, during acute EAE in both groups, IL-6 expres-
sion was undetectable in Iba-1+ cells (Figure 1B). These
data demonstrate that the predominant source of IL-6
during acute EAE is not altered by the inability of astro-
cytes to respond to IFN-γ. Neither the cell type(s) se-
creting IL-6 nor their anatomical location relative to
the white matter lesions has been established during ei-
ther chronic or progressive forms of EAE. In contrast
to WT mice, where astrogliosis is diminished during
chronic EAE and limited to white matter areas, astro-
cyte activation is sustained during progressive disease
in GFAPγR1Δ mice, including in gray matter distal
from the demyelinating lesions [9]. Although the num-
ber of cells secreting IL-6 in the absence of IFN-γ sig-
naling to astrocytes was increased relative to WT mice,
IL-6+ cells in mice with progressive EAE were located
within white matter areas (Figure 1C), similar to the
distribution in WT mice. Moreover, IL-6 remained un-
detectable in Iba-1+ cells (data not shown) and co-
localized mainly with GFAP+ cells located within or ad-
jacent to areas of myelin loss (Figure 1D), supporting
astrocytes as the primary source of IL-6 during both
acute and chronic EAE. Although IFN-γ signaling limits
astrocyte activation to areas of demyelination, IL-6
Figure 1 Astrocytes produce IL-6 during chronic EAE. IL-6 co-localizes with GFAP+ astrocytes (A) in both WT and GFAPγR1Δ mice during the
acute EAE, but not with Iba-1+ macrophage/microglia (B). Bars = 25 μm in the main panel, 5 μm in the insets. (C) During resolving (WT mice) and
progressive (GFAPγR1Δ mice) EAE at day 35 post immunization, IL-6-secreting cells were restricted to white matter areas within the spinal cord of
both WT and GFAPγR1Δ mice. Bar = 200 μm in the main figure, bar = 50 μm in the inset. (D) During progressive EAE, activated astrocytes are
found in both gray matter (marked with a dashed line) and white matter lesion areas. No astrocytes producing IL-6 were detected in the gray
matter (yellow frame). Only astrocytes in or around white matter lesions produced IL-6 (cyan frame). Images were obtained from the lumbar
segments of both WT and GFAPγR1Δ mice and are representative of three mice per group. Bar = 50 μm.
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astrocytes associated with the areas of myelin loss se-
creted IL-6 during chronic EAE.
IL-6 limits clinical improvement
IL-6 has been implicated in the pathogenesis of MS, and
its inhibition is efficacious in treating human peripheral
autoimmune diseases [37]. Moreover, IL-6 blockade
prior to, or concomitant with, induction of EAE elimi-
nated both clinical disease and CNS inflammation
[17,38]. Although IL-6 blockade after initial EAE clinical
symptoms appeared was ineffective [38], the contribu-
tion of IL-6 to progressive EAE remains unknown.
GFAPγR1Δ mice exhibiting essentially identical clinical
symptoms at the peak of EAE were therefore divided
into two treatment groups (see Figure 2A,C). One group
was treated by intraperitoneal injection of 500 μg neu-
tralizing anti-IL-6 mAb, while the other group received
an equal amount of isotype control rat IgG mAb. Fol-
lowing initial treatment, all mice were treated every third
day for a total of four injections. Diminution of clinical
disease severity was readily apparent after the initial in-
jection of anti-IL-6 mAb (Figure 2A), and a reduction in
the progression of clinical symptoms was sustained by
IL-6 neutralization (Figure 2A,C). In contrast to the re-
solving disease in WT mice, sustained clinical disease in
GFAPγR1Δ mice is associated with accumulating mor-
tality (Figure 2B). Anti-IL-6 treatment improved survivalof GFAPγR1Δ mice during progressive EAE, reducing
mortality from 52% to 24% (Figure 2B). To determine if
IL-6 neutralization also promoted recovery in non-
progressive EAE, an identical experiment was carried
out in WT mice. Similar to GFAPγR1Δ mice, mice were
divided into two groups at the peak of clinical disease
and one group received anti-IL-6 and the other isotype
control mAb (Figure 2A,D). Although improvement of
symptoms was less than that observed during progres-
sive disease in GFAPγR1Δ mice (Figure 2A), anti-IL-6
treatment of WT mice with EAE also mediated a reduc-
tion of approximately 0.7 score units compared to the
control group (Figure 2A,D). Thus, these data demon-
strate that IL-6 blockade limits mortality and promotes
recovery during a paralytic autoimmune disease associ-
ated with progressive disability and to a lesser extent dur-
ing resolving conditions.
IL-6 enhances tissue damage during progressive EAE
Demyelination and axonal damage, hallmarks of EAE as
well as relapsing remitting and chronic progressive MS
[1], contribute to clinical disease. To determine if re-
duced clinical disease severity during progressive EAE
mediated by anti-IL-6 treatment correlated with reduced
tissue damage, individual spinal cords from the treated
and isotype control mice were analyzed at six levels,
4 days following the last treatment. The extensive de-
myelination associated with the inability of astrocytes to
Figure 2 Anti-IL-6 treatment ameliorates clinical disease. GFAPγR1Δ and WT mice were separated into two groups with identical clinical scores at
the peak of EAE and received either the isotype control α-β-gal or α-IL-6 mAb treatment. (A) Disease progression was inhibited in GFAPγR1Δ mice
and recovery was promoted in WT mice by anti-IL-6 treatment. Arrowheads represent time of injection. (B) Minimal mortality in WT mice treated
with α-β-gal or α-IL-6 mAb. Survival decreased in GFAPγR1Δ mice treated with isotype control mAb. By contrast, mortality was reduced by treatment
of GFAPγR1Δ mice with α-IL-6 mAb. Kaplan-Meier survival curves with *P < 0.05, ***P < 0.001, log-rank test. (C, D) At day 32 post immunization
(12 days after initial α-IL-6 treatment), both GFAPγR1Δ (C) and WT (D) mice treated with α-IL-6 exhibited improved clinical disease. Statistical
differences determined by a two-tailed unpaired t test. Data represent the average ± SEM with GFAPγR1Δ + α-β-gal (n = 33), GFAPγR1Δ + α-IL-6
(n = 30), WT+ α-β-gal (n = 20), and WT+ α-IL-6 (n = 20) from at least three separate experiments.
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(Figure 3A). The extent of protection averaged over six sec-
tions in multiple animals demonstrated approximately 40%
reduction in the white matter areas involved in myelin loss
(Figure 3B). Axonal damage, a possible contributor to
decreased disability [39], was examined by determining
APP expression as well as phosphorylated and non-
phosphorylated neurofilaments. Both approaches indi-
cated that axonal damage was confined to areas within
lesions and correlated with the extent of demyelination.
Importantly, IL-6 mAb treatment reduced the extent ofnot only myelin damage but also axonal damage within
the lesions (Figure 3C,D). These data demonstrate that
sustained IL-6 secretion by astrocytes enhances clinical
disease as well as both the extent of demyelination and
its associated axonal damage.
IL-6-independent astrogliosis
Astrogliosis, induced by virtually all perturbations of the
CNS environment [40], is also associated with white
matter lesions in MS and EAE [41]. Progressive EAE in
GFAPγR1Δ mice showed extended astrocyte activation
Figure 3 Inhibition of disease progression in GFAPγR1Δ mice correlates with decreased demyelination and axonal damage. Spinal cord sections of
GFAPγR1Δ mice treated with α-β-gal and α-IL-6 mAbs at day 32 post immunization stained with LFB (A) or anti-APP (C) to assess demyelination
and axonal damage, respectively. Representative sections from three experiments with three individual mice per group per experiment. In (A), areas
of demyelination are shown with arrows. Bar = 200 μm. (B) Percentage area of demyelination in spinal cord white matter calculated by analysis of
transverse sections at six separate levels per mouse. Data represent the mean ± SEM of seven to nine individual mice per group from two separate
experiments. APP+-damaged axons (C) shown with arrows. Bar = 100 μm. (D) Number of APP+ axons per 100-μm2 area of demyelination analyzed
in GFAPγR1Δ mice treated with α-β-gal and α-IL-6 mAb at day 32 post immunization. Data represent the mean ± SEM of four to five individual mice
per group from two separate experiments. Statistical differences determined by a two-tailed unpaired t test with *P < 0.05.
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myelinating lesions [9]. IL-6 is one of several molecules
supporting astrogliosis [42,43]. We therefore considered
the possibility that increased IL-6 within the CNS of
GFAPγR1Δ mice with progressive EAE accounted for, or
contributed to, either the sustained astrogliosis or the
unique global distribution of activated astrocytes in the gray
matter. Comparative analysis of mRNA encoding GFAP, a
marker of astrocyte activation, during progressive EAE con-
firmed increased astrocyte activation in GFAPγR1Δ mice
relative to WT mice (Figure 4A). However, GFAPγR1Δ
mice treated with anti-IL-6 exhibited only a minor trend to-
ward decreased GFAP mRNA expression (Figure 4A), sug-
gesting that although IL-6 secretion was sustained in the
areas of white matter damage (Figure 1), it did not contrib-
ute to the sustained global astrocyte activation. This was
confirmed by comparing the distribution of activated astro-
cytes in the control and anti-IL-6-treated groups. Neither
numbers of activated astrocytes within, or adjacent to,
demyelinating areas nor those in the gray matter were
affected by IL-6 neutralization (Figure 4B). These
observations suggest that clinical improvement, dimin-
ished demyelination, and limited axonal damage medi-
ated by IL-6 neutralization are independent of overall
astrocyte activation.IL-6 regulated CNS inflammation
The contribution of inflammation to the disability asso-
ciated with MS and EAE is unclear. Nevertheless,
astrocytes are critical in limiting the autoimmune in-
flammatory response [44], and their IL-6 secretion may
enhance autoimmune inflammation by preventing Tcell
apoptosis [11]. To determine if IL-6 influenced CNS in-
flammation, bone marrow-derived CD45hi inflamma-
tory cells within the CNS were examined by flow
cytometry. Increased numbers of inflammatory cells in
the CNS of mice with progressive EAE relative to
resolving disease confirmed IFN-γ signaling to astrocytes
regulates the magnitude of inflammation (Figure 5A).
Neutralization of IL-6 reduced the number of CNS inflam-
matory cells to approximately the same level as in WT mice
with resolving EAE (Figure 5A), suggesting that increased
inflammation associated with the inability of astrocytes to
respond to IFN-γ signaling is due, at least in part, to sus-
tained IL-6 secretion. Despite the correlation of reduced
CNS inflammation with clinical improvement, reduced
demyelination, reduced axonal damage, and decreased
disability, anti-IL-6 treatment did not alter the overall dis-
tribution of inflammatory cells, which remained in both
perivascular and intra-parenchymal locations within the le-
sion areas (Figure 5B).
Figure 4 IL-6 blockade has a limited effect on astrocyte activation. (A) GFAP mRNA expression analyzed by real-time PCR at day 32 post
immunization in the spinal cords of WT, GFAPγR1Δ + α-β-gal, and GFAPγR1Δ + α-IL-6 mice with n = 3 to 4 individual mice per group. Statistics
were calculated with one-way ANOVA with Bonferroni post-test with ***P < 0.001. (B) Immunohistochemical staining for GFAP in WT, GFAPγR1Δ +
α-β-gal, and GFAPγR1Δ + α-IL-6 mice. Upper panels show GFAP labeling within areas of white matter demyelination. Lower panels show GFAP
labeling in gray matter distal from areas of demyelination. Bar = 50 μm.
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tion while potentially inhibiting Treg function [22,45],
but its role in regulating effector T cell populations
within the CNS during progressive EAE has not been
described. Flow cytometric analysis revealed only minor
alterations in total CD4+ T cell numbers, with a slight
decrease induced by anti-IL-6 treatment (Figure 5C).
Whereas IL-6 neutralization had only a limited effect on
overall CD4+ T cells, it may be protective by modifying
the frequency of effector T cells or Treg. The relative
frequencies of effector T cells secreting IFN-γ and IL-17,
as well as the frequency of Treg, were compared within
the CNS of GFAPγR1Δ mice treated with anti-IL-6 or
control mAb during progressive EAE, as well as in WT
mice with EAE. No differences in the frequency of CD4+
T cells secreting IFN-γ (Figure 6A) or IL-17 (Figure 6B)
were detected after anti-IL-6 treatment of GFAPγR1Δ
mice. In addition, there were no changes in Foxp3+ Treg
which correlated with anti-IL-6-mediated protection
(Figure 6C). Decreased inflammation mediated by IL-6
neutralization is consistent with limiting apoptosis [11].
However, only a limited number of caspase 3+ cells weredetected in the spinal cords of either GFAPγR1Δ or WT
mice at 32 days post immunization (data not shown).
Furthermore, no differences in the anatomical location
of caspase 3+ cells were noted, irrespective of the treat-
ment group, supporting the absence of an IL-6-mediated
inhibition of anti-apoptotic protection. These data sug-
gested that neutralization of IL-6 influenced the overall
inflammation by decreasing proliferation, rather than fa-
cilitating apoptosis or altering the frequency of effector
T cells or Treg.
IL-6-dependent proliferation of inflammatory cells was
examined via a pulse of BrdU. During acute EAE, num-
bers of proliferating CNS inflammatory cells were simi-
lar in WT and GFAPγR1Δ mice (Figure 7A). By contrast,
proliferation of CNS inflammatory cells was sustained
during progressive EAE, while it declined in WT mice
(Figure 7A). Consistent with a reduction of CNS inflam-
mation in GFAPγR1Δ mice treated with anti-IL-6 mAb,
proliferation declined to levels equivalent to those in
WT mice during chronic EAE (Figure 7A). Analysis of
CD4+ T cell proliferation (Figure 7B) confirmed a limited
alteration in CD4+ T cells (Figure 5C). Although the
Figure 5 Inflammatory leukocytes during progressive EAE are reduced by IL-6 blockade. (A) Total number of bone marrow-derived inflammatory cells
(CD45hi). Data represent the mean ± SEM of two separate experiments with n = 4 per group per experiment. Statistics were calculated with one-way
ANOVA with Bonferroni post-test with **P < 0.01; ***P < 0.001. (B) Inflammatory cells within the spinal cord sections of GFAPγR1Δ mice treated with
α-β-gal or α-IL-6 mAb at day 32 post immunization identified with H&E. Inflammatory cells were limited to lesions and were both perivascular (arrows)
and within the parenchyma. Bar = 50 μm. Representative sections from two experiments with four individual mice per group per experiment. (C) CD4+
T cells (CD45hiCD4+) within the CNS of WT, GFAPγR1Δ + α-β-gal, and GFAPγR1Δ + α-IL-6 mice analyzed by flow cytometry at day 32 post immunization.
Data represent the mean ± SEM of two separate experiments with n= 4 per group per experiment.
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mice was reduced by IL-6 neutralization to approxi-
mately the level of CD4+ T cell proliferation in WT
mice, the reduction did not reach statistical significance
(Figure 7B). These data suggest that within the CNS,
IL-6 facilitates proliferation of inflammatory cells other
than CD4+ T cells.
IL-6 regulated microglia activation
Recruitment of bone marrow-derived macrophages (BMDM)
into the CNS is required for demyelination during acute
EAE [46,47]; however, the relative contribution of mac-
rophages and microglia to tissue damage during pro-
gressive MS or EAE is unclear. IL-6 stimulates microglia
proliferation in vitro [48] and microglia activation
in vivo [43]. Flow cytometric analysis of CD45hi BMDM
and CD45lo microglia showed that progressive EAE was
associated with an increased number of both BMDMFigure 6 CD4+ T cell response is not altered by anti-IL-6 treatment. Freque
GFAPγR1Δ + α-IL-6 mice producing IFN-γ (A) and IL-17 (B) as well as cells e
immunization. Data represent the mean ± SEM of two separate experimentand microglia relative to WT mice, which declined to
WT levels following IL-6 neutralization (Figure 8A,B).
A pulse of BrdU was employed to determine if the in-
crease in BMDM and microglia in GFAPγR1Δ mice
relative to WT mice correlated with increased IL-6-
mediated proliferation. BMDM proliferation was simi-
lar in all groups during chronic EAE (Figure 8C), and
microglia proliferation in WT mice remained at low
levels during chronic EAE (Figure 8C). By contrast,
microgliosis was increased in GFAPγR1Δ mice during
progressive EAE (Figure 8D). Consistent with its thera-
peutic effects, IL-6 neutralization decreased microglia
proliferation to approximately the levels in WT mice
(Figure 8D). Sustained proliferation suggested that the
inability of astrocytes to respond to IFN-γ correlated with
sustained microglial activation. Major histocompatibility
complex (MHC) class II expression, as a measure of both
activation and potential for antigen presentation, wasncies of CD4+ T cells within the CNS of WT, GFAPγR1Δ + α-β-gal, and
xpressing Foxp3 (C) determined by flow cytometry at day 32 post
s with n = 4 pooled mice per group per experiment.
Figure 7 Proliferation of inflammatory cells during progressive EAE is reduced by anti-IL-6 treatment. (A) Proliferation of CD45hi cells within the
CNS of WT and GFAPγR1Δ mice during acute EAE (day 20 post immunization) or WT, GFAPγR1Δ + α-β-gal, and GFAPγR1Δ + α-IL-6 mice during
chronic EAE (day 32 post immunization) measured by BrdU staining and flow cytometry. Four individual mice were analyzed per group per time
point. (B) Percentage of BrdU-positive cells within CD4+ cells analyzed at day 32 post immunization in WT and GFAPγR1Δ mice treated with
α-β-gal or α-IL-6 mAb. Data represent the mean ± SEM of two separate experiments with n = 4 per group per experiment. Statistics were calculated
with one-way ANOVA with Bonferroni post-test with *P < 0.05.
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and microglia derived from GFAPγR1Δ mice with pro-
gressive EAE compared to the respective populations de-
rived fromWTcontrols (Figure 8E). The increase in class
II-expressing microglia was more dramatic (2% in WTvs.
12% in GFAPγR1Δ mice) compared to the minimal in-
crease in class II-expressing BMDM (9% inWTvs. 12% in
GFAPγR1Δ mice). Coupled with increased proliferation,
these data suggest that the inability of astrocytes to re-
spond to IFN-γ results in sustained microglial activation,
possibly due to a diminished ability of astrocytes to
secrete microglial inhibitory molecules, which are ame-
liorated by IL-6 neutralization. Galectin-1 and heme
oxygenase 1 (HO-1) participate in the astrocyte and
microglia crosstalk and contribute to the regulation of
CNS inflammation [30,33]. Astrocyte-derived Galectin-1
deactivates microglia during EAE [33], whereas increased
HO-1 in microglia is regulated by astrocytes [49]. Both
Galectin-1 and HO-1 mRNA expression were increased
in GFAPγR1Δ mice with progressive EAE receiving anti-
IL-6 treatment (Figure 8F), supporting the concept that
IFN-γ signaling to astrocytes is essential in limiting IL-6
secretion by astrocytes and reducing microglia activation.
Discussion
Induction of EAE in mice in which IFN-γ signaling to
astrocytes is inhibited results in a progressive form of
EAE characterized by sustained paralytic disease, de-
myelination, axonal damage, and escalating mortality. A
hallmark of this progressive disease, distinguishing it
from the resolving form, is global astrocyte activationindicated by hypertrophic astrocytes with increased GFAP
expression. Although astrogliosis is associated with white
matter lesions in both the acute and chronic forms of
non-progressive EAE, activation in progressive EAE was
more global including astrocytes within gray matter areas
[9]. Progressive EAE also correlated with diminished anti-
inflammatory cytokines and increased pro-inflammatory
cytokines, including IL-6 [9]. IL-6, although undetectable
in the naïve CNS, may contribute to physiological pro-
cesses such as astrogliogenesis and neuronal differenti-
ation [50] and has also been implicated in a variety of
chronic CNS diseases including MS, Alzheimer’s, Parkin-
son’s, and Huntington’s diseases [50]. In both patients with
MS and during acute EAE, astrocytes are the major source
of IL-6 [15,16], suggesting that the increase in IL-6 re-
sulted from the sustained astrogliosis in the absence of
IFN-γ signaling. Nevertheless, IL-6 secretion is limited to
astrocytes proximal to areas of demyelination, suggesting
an intimate relationship between IL-6 secretion and mye-
lin loss, which led us to investigate the pathogenic role of
IL-6 during progressive EAE.
Neutralization of IL-6 during the chronic progressive
phase of EAE limited disease progression, which corre-
lated with decreased demyelination and axonal damage,
hallmarks of the CNS lesions in patients with relapsing
remitting and progressive MS [51]. Nevertheless, de-
creased tissue damage following IL-6 inhibition did not
reduce the extent of astrogliosis, suggesting that IL-6
does not contribute to sustained astrocyte activation and
that its protective effect is independent of astrogliosis, at
least over the time course of these experiments. Moreover,
Figure 8 Increased microgliosis characteristic of progressive EAE is decreased after anti-IL-6 treatment. Total number of macrophages (CD45hiCD11b+) (A)
and microglia (CD45loCD11b+) (B) within the CNS of WT and GFAPγR1Δ mice treated with α-IL-6 or α-β-gal mAb at day 32 post immunization. Percentage
of BrdU-positive macrophages (CD45hiCD11b+) (C) and microglia (CD45loCD11b+) (D) in WT and GFAPγR1Δ mice treated with α-β-gal or α-IL-6 analyzed at
day 32 post immunization by flow cytometry. Data represent the mean ± SEM of two separate experiments with n= 4 per group per experiment. Statistics
calculated with one-way ANOVA with Bonferroni post-test with *P< 0.05; **P< 0.01. (E) Microglia activation, characterized by MHC class II expression within
CD45loCD11b+ cells, analyzed at day 32 post immunization by flow cytometry in WT, GFAPγR1Δ+ α-β-gal, and GFAPγR1Δ+ α-IL-6 mice. (F) Galectin-1 and
heme oxygenase-1 mRNA expression within the brain of GFAPγR1Δ mice treated with α-β-gal or α-IL-6 at day 32 post immunization. Data represent the
mean ± SEM of four individual mice per group. Statistics were calculated with by a two-tailed unpaired t test with *P< 0.05.
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treated WT or GFAPγR1Δ mice (data not shown), as was
observed in mice treated with anti-IL-6 prior to disease on-
set [52]. IL-6 blockade during progressive EAE correlated
with decreased CNS inflammation, suggesting the possibil-
ity that IL-6 directly alters the response of self-reactive T
cells. Indeed, as a component of peripheral immune activa-
tion, IL-6 regulates Tcell activation and cytokine secretion,
limits Treg-suppressive activity, and alters the endothelial
cells associated with the blood–brain barrier, thereby con-
trolling T cell egress into the CNS parenchyma [22,53].
Nevertheless, blocking IL-6 prior to the onset of acute EAE
has led to conflicting results. Indeed, IL-6 blockade pre-
vented EAE development by limiting both Th1 and Th17
cell differentiation [16,38,52]. By contrast, Willenborg et al.
[54] were unable to detect any effect of anti-IL-6 treatment;
IL-6 blockade initiated at disease onset also had little effect
on disease development [38], consistent with the concept
that disease progression during acute EAE is IL-6 inde-
pendent once T cells are activated. The present data show
that inhibition of IL-6 during progressive EAE reduced in-
flammation without altering the frequency of either Th17or Th1 cells, again suggesting a mode of action distinct
from IL-6 blockade prior to disease onset [38]. In support
of a mechanism independent of autoimmune T cell activa-
tion within the CNS, Foxp3+ Treg were not increased
within the CNS following sustained IL-6 neutralization,
although IL-6 is reported to limit Treg activity via sup-
pressing Foxp3 expression [23]. In addition, no effects on
apoptotic cell numbers by anti-IL-6 treatment implied
protection was independent of IL-6 anti-apoptotic activity
[11]. IL-6 also had a limited effect on sustaining CD4 T
cell proliferation during progressive EAE. Moreover, the
inability of astrocytes to present class II antigen in the
context of in vivo inflammation [55] suggested an indirect
effect of sustained IL-6 secretion on antigen presenting
cells in supporting self-reactive T cell activation.
IFN-γ signaling to astrocytes limited the overall inflamma-
tory response within the CNS [9]. The increased CNS
inflammation during progressive EAE correlated with in-
creased numbers of BMDM and activated microglia exhibit-
ing sustained MHC class II expression. IL-6 neutralization
reduced the number of both activated BMDM and microglia,
although IL-6 preferentially increased microglial proliferation.
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IL-6 blockade more efficiently on microglia. This observation
may explain the limited effect of anti-IL-6 treatment on
CD4+ T cell proliferation, as microglia exhibit limited antigen
presentation functions in vivo [56,57]. These data suggest
that increased tissue damage may correlate with the inability
of the astrocyte to down regulate microglial activity in the
absence of IFN-γ signaling. Recent in vivo data support the
concept that astrocytes regulate microglial activity during in-
flammation. Inhibition of NF-κB in astrocytes diminished
clinical disease during EAE by attenuating microglia activa-
tion [29,30]. Similarly, Galectin-1 secretion by astrocytes
limits both microglial activation and EAE [33], whereas
astrocyte-mediated induction of HO-1 in microglia limits
neuroinflammation [49]. Increased expression of both
Galectin-1 and HO-1 after anti-IL-6 treatment, associated
with decreased microglia proliferation and MHC class II ex-
pression, thus supports the concept that the crosstalk be-
tween astrocytes and microglia during the chronic phase of
EAE is essential for disease resolution. However, it remains
unclear whether astrocyte-derived IL-6 acts directly on
microglia or indirectly via an autocrine-induced alteration in
astrocyte function [58]. It is also possible that IL-6 itself alters
astrocyte functions, which also contributes to tissue dam-
age during progressive EAE. Astrocytes regulate diverse
CNS functions from neurogenesis to defending from both
internal and external insults [40]. Their critical contribu-
tions to regulating chronic CNS autoimmune disease are
supported by the expanding number of alterations in
astrocyte function that result in progressive types of EAE
[9,59,60]. Furthermore, detrimental effects of IL-6 secre-
tion by astrocytes on CNS function and pathobiology are
exemplified by analysis of mice in which IL-6 is constitu-
tively expressed by astrocytes [61]. Sustained IL-6 results
in localized neuroinflammation, neurodegeneration, loss
of blood–brain barrier integrity, and impaired learning
[31,62,63]. Finally, reduced disease severity after elimin-
ation of B cells secreting IL-6 in two EAE models as well
as in patients with relapsing remitting MS [64,65] supports
a destructive role for IL-6 during CNS autoimmunity.
Conclusions
These data demonstrate that one anti-inflammatory activity
of IFN-γ is to prevent sustained IL-6 expression by astro-
cytes, which plays an essential role in disease progression
during progressive EAE. IL-6 is critical in mediating de-
myelination, axonal damage, and sustaining both CNS in-
flammation and disability during progressive EAE. These
data demonstrated the therapeutic potential of IL-6 block-
ade in limiting both the disability and tissue damage in a
model of progressive EAE. This approach, currently in use
to treat patients with peripheral autoimmune disease, may
thus be efficacious in the treatment of the progressive
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